SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8 | -97.9% | 6,000 | -29.2% | 0.00% | -98.1% |
| Q2 2023 | $381 | +14.8% | 8,480 | +2.2% | 0.05% | +55.9% |
| Q1 2023 | $332 | +6.1% | 8,300 | -17.0% | 0.03% | +30.8% |
| Q4 2022 | $313 | -99.9% | 10,000 | -12.3% | 0.03% | +18.2% |
| Q3 2022 | $327,000 | +15.5% | 11,400 | -15.4% | 0.02% | +10.0% |
| Q2 2022 | $283,000 | -20.1% | 13,470 | +2.6% | 0.02% | +11.1% |
| Q1 2022 | $354,000 | +2.9% | 13,135 | -47.5% | 0.02% | +20.0% |
| Q4 2021 | $344,000 | +5.2% | 25,000 | +153.0% | 0.02% | 0.0% |
| Q3 2021 | $327,000 | +101.9% | 9,880 | -58.2% | 0.02% | +114.3% |
| Q2 2021 | $162,000 | -56.6% | 23,640 | +84.3% | 0.01% | -61.1% |
| Q1 2021 | $373,000 | +81.1% | 12,826 | -29.2% | 0.02% | +80.0% |
| Q4 2020 | $206,000 | +505.9% | 18,124 | +255.4% | 0.01% | +400.0% |
| Q3 2020 | $34,000 | -43.3% | 5,100 | -48.5% | 0.00% | -50.0% |
| Q2 2020 | $60,000 | +3.4% | 9,900 | +330.4% | 0.00% | +33.3% |
| Q1 2020 | $58,000 | -91.7% | 2,300 | -95.8% | 0.00% | -93.0% |
| Q4 2019 | $702,000 | +207.9% | 55,271 | +186.4% | 0.04% | +104.8% |
| Q3 2019 | $228,000 | +19.4% | 19,300 | +183.8% | 0.02% | +23.5% |
| Q2 2019 | $191,000 | -61.3% | 6,800 | -84.0% | 0.02% | -66.7% |
| Q1 2019 | $493,000 | +84.6% | 42,600 | +43.9% | 0.05% | +96.2% |
| Q4 2018 | $267,000 | +78.0% | 29,600 | +184.6% | 0.03% | +160.0% |
| Q3 2018 | $150,000 | -60.5% | 10,400 | -1.9% | 0.01% | -66.7% |
| Q2 2018 | $380,000 | -13.6% | 10,600 | -61.7% | 0.03% | -18.9% |
| Q1 2018 | $440,000 | -89.5% | 27,693 | -75.2% | 0.04% | -78.4% |
| Q4 2017 | $4,190,000 | +413.5% | 111,890 | -1.1% | 0.17% | +470.0% |
| Q3 2017 | $816,000 | -75.2% | 113,111 | -27.9% | 0.03% | -75.2% |
| Q2 2017 | $3,286,000 | +447.7% | 156,842 | +71.0% | 0.12% | +384.0% |
| Q1 2017 | $600,000 | -35.3% | 91,720 | +108.1% | 0.02% | -24.2% |
| Q4 2016 | $928,000 | -17.9% | 44,080 | -75.4% | 0.03% | -35.3% |
| Q3 2016 | $1,131,000 | +35.9% | 179,323 | +68.6% | 0.05% | +21.4% |
| Q2 2016 | $832,000 | +845.5% | 106,368 | +771.9% | 0.04% | +600.0% |
| Q1 2016 | $88,000 | -39.7% | 12,200 | +84.8% | 0.01% | -25.0% |
| Q4 2015 | $146,000 | – | 6,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Integral Health Asset Management, LLC | 409,000 | $17,399,000 | 4.82% |
| Palo Alto Investors LP | 781,730 | $33,255,000 | 2.12% |
| DAFNA Capital Management LLC | 180,306 | $7,670,000 | 1.93% |
| Boxer Capital, LLC | 1,094,000 | $46,539,000 | 1.81% |
| Deep Track Capital, LP | 500,000 | $21,270,000 | 1.50% |
| Bellevue Group AG | 3,228,004 | $137,319,000 | 1.42% |
| EcoR1 Capital, LLC | 940,636 | $40,015,000 | 1.28% |
| Deep Track Capital, LP | 400,000 | $17,016,000 | 1.20% |
| Artal Group S.A. | 1,000,000 | $42,540,000 | 1.15% |
| SECTOR GAMMA AS | 98,904 | $4,207,000 | 0.99% |